Mikkael A. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times, he is the author of When Blood Breaks Down: Life Lessons from Leukemia (MIT Press).

• Preface ix1 This Little Drug Came to Market... 12 And Finally, Efficacy 293 The Moxie to Do Battle 534 Trials and Tribulations 775 Starve a Tumor, Feed an Industry 1076 A Viral Scourge 1317 Silence = Death 1558 The FDA Makes Its Case 1859 The Avastin Decision 215Epilogue 247Acknowledgments 259Appendix 261Notes 267Index 299

"It’s a physician’s-eye-view on the products that fill our medicine cabinets, but Sekeres includes patients in the mix, too. A public that, in his words, 'revolts, protesting loudly enough to be heard, to provoke change' is the true driver of this engaging book."—Erin Blakemore, The Washington Post“A thought-provoking book that confronts readers with all of these difficult questions while keeping them glued to their seats through Sekeres’s skillful and self-reflective retelling of the Avastin hearings.”—Bill of Health, Harvard Law School

Mikkael A. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times, he is the author of When Blood Breaks Down: Life Lessons from Leukemia (MIT Press).

• Preface ix1 This Little Drug Came to Market... 12 And Finally, Efficacy 293 The Moxie to Do Battle 534 Trials and Tribulations 775 Starve a Tumor, Feed an Industry 1076 A Viral Scourge 1317 Silence = Death 1558 The FDA Makes Its Case 1859 The Avastin Decision 215Epilogue 247Acknowledgments 259Appendix 261Notes 267Index 299

"It’s a physician’s-eye-view on the products that fill our medicine cabinets, but Sekeres includes patients in the mix, too. A public that, in his words, 'revolts, protesting loudly enough to be heard, to provoke change' is the true driver of this engaging book."—Erin Blakemore, The Washington Post“A thought-provoking book that confronts readers with all of these difficult questions while keeping them glued to their seats through Sekeres’s skillful and self-reflective retelling of the Avastin hearings.”—Bill of Health, Harvard Law School

Mikkael A. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times, he is the author of When Blood Breaks Down: Life Lessons from Leukemia (MIT Press).

• Preface ix1 This Little Drug Came to Market... 12 And Finally, Efficacy 293 The Moxie to Do Battle 534 Trials and Tribulations 775 Starve a Tumor, Feed an Industry 1076 A Viral Scourge 1317 Silence = Death 1558 The FDA Makes Its Case 1859 The Avastin Decision 215Epilogue 247Acknowledgments 259Appendix 261Notes 267Index 299

"It’s a physician’s-eye-view on the products that fill our medicine cabinets, but Sekeres includes patients in the mix, too. A public that, in his words, 'revolts, protesting loudly enough to be heard, to provoke change' is the true driver of this engaging book."—Erin Blakemore, The Washington Post“A thought-provoking book that confronts readers with all of these difficult questions while keeping them glued to their seats through Sekeres’s skillful and self-reflective retelling of the Avastin hearings.”—Bill of Health, Harvard Law School